Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-12-056578
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-12-10 12:44:19
Reporting Period:
2012-12-07
Filing Date:
2012-12-10
Filing Date Changed:
2012-12-10
Accepted Time:
2012-12-10 12:44:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
887151 Capstone Therapeutics Corp. CAPS Pharmaceutical Preparations (2834) 860585310
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
949119 Iii I Lloyd Miller 222 Lakeview Avenue
Suite 160-365
West Palm Beach FL 33401
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-12-07 97,250 $0.16 4,237,468 No 4 P Indirect By Trust A-4 - Lloyd I. Miller
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Trust A-4 - Lloyd I. Miller
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 472,792 Indirect By Milfam II L.P.
Common Stock 90,344 Indirect By Trust D - Lloyd I. Miller
Common Stock 641,218 Indirect By Milgrat Q8
Common Stock 724,100 Indirect By Milfam NG LLC
Common Stock 58,967 Direct
Footnotes
  1. The price in Column 4 is a weighted average price. The price actually paid ranged from $0.15 to $0.163 per share. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
  2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. This filing shall not be deemed an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of any equity securities covered by this filing.